Business Wire

SC-ENVIVA-FOREST-FUND

20.9.2022 18:04:36 CEST | Business Wire | Press release

Share
The Enviva Forest Conservation Fund Announces its 2022 Grant Recipients

The Enviva Forest Conservation Fund (the Fund) today announced the recipients of its 2022 grants. The projects funded this year will help conserve more than 3,000 acres and protect ecologically sensitive bottomland hardwood forests in the Virginia-North Carolina coastal plains.

Including those announced today, the Fund has awarded 29 projects totaling more than $3,100,000 in grants over the past seven years. An estimated 33,000 acres will be protected when these projects reach completion. The forests conserved as a part of the Fund help clean drinking water, purify the air, buffer structures from storms, and provide habitat for many species of wildlife, while at the same time, providing jobs and economic opportunity for rural families and private landowners.

“The fund is well on its way to achieving its initial goal to protect over 35,000 acres of sensitive bottomland hardwood forests across Virginia and South Carolina,” said Thomas Meth, President of Enviva. “With more than three years left in the program, the Fund is poised to partner with more and more diverse conservation groups as well as supersede our commitment to long-term investments in forest stewardship for generations to come.”

The 2022 Enviva Forest Conservation Fund grant recipients include:

The Tar River Land Conservancy: Tar River Land Conservancy aims to purchase the Bowers Tract, consisting of 244 forested acres and 60 acres of agricultural upland fields. Fifty-four percent (219 acres) of the property is situated within the 100-year-old floodplain of Swift Creek, a major tributary of the Tar River. Adjoining the property, Swift Creek provides a habitat for numerous rare, threatened, and endangered aquatic species, including the federally protected Carolina Madtom, Tar River Spiny Mussel, and Neuse River Waterdog.

Three Rivers Land Conservancy: Three Rivers Land Conservancy aims to acquire 440 acres of bottomland hardwood forest adjacent to the Little River and Uwharrie National Forest in Montgomery County, North Carolina. The Little River Buffer and Cliffs natural areas are located on the property. Federally endangered Northern Long Eared Bat and the threatened Oak Toad, Alewife, and Blue Back Herring are all present within this forest acreage.

The Virginia Outdoors Foundation: The Virginia Outdoors Foundation aims to acquire the Turner Tract which lies on the state scenic Nottoway River near Cary's Bridge. This tract contains 134 acres of bottomland hardwoods (111 acres of general hardwoods and 23 acres of Cypress-Tupelo) which will be designated as "old growth" as well as hundreds of acres of working forest. This land contributes to the protected corridor on the Nottoway River and its conservation will support the effort to protect this unique and fragile Virginia resource with a “National Wild and Scenic River” designation. The balance of the tract will remain in working forest and/or agricultural use.

The Conservation Fund: The Conservation Fund will protect 1,915 acres dominated by native bottomland hardwoods, forested wetlands, and loblolly pine along the Nottoway River in Sussex County, Virginia. This project will add to the corridor of protected land along the Nottoway River with 3.5 miles of frontage along the Nottoway where federally endangered Roanoke Logperch and Dwarf Wedge Mussel are found. The property also features 2.5 miles of frontage on Black Branch Swamp, where over 220 acres of forested wetlands and 400 acres of bottomland hardwoods reside. Sustainable forest management and restoration to native longleaf pine and pine savanna on the property will help create a habitat for endangered species such as the Red-Cockaded Woodpecker. Once transferred to the Virginia Department of Wildlife Resources, the property will be open for hunting, hiking, fishing, boating, and wildlife watching.

Ducks Unlimited: Ducks Unlimited aims to acquire a total of 292 acres in Bertie and Gates counties in North Carolina, under two separate tracts - the Crawford Tract and the Gasking Swamp Tract. The Crawford Tract is home to the Red-Cockaded Woodpecker and will expand the adjacent (on 3 sides) Chowan Swamp Game Land, which is located in one of the most important river basins for anadromous fishes in North Carolina. The Gasking Swamp Tract will expand the adjacent Bertie County Game Land, which helps protect portions of the Cashie River Swamps’ small creeks, floodplain wetlands, and Significant Natural Heritage Areas. These tracts provide important travel corridors for black bears along the Cashie River and are recognized as a “Global Important Bird Area.”

“The Endowment continues to support the efforts of the Enviva Forest Conservation Fund. These long-term investments promote conservation, biological diversity, and ecosystem sustainability in these areas of North Carolina and Virginia,” said Teal Edelen, Program Officer at the U.S. Endowment for Forestry and Communities. “These grants support sources of clean air and water, protect threatened wildlife and plant life, and provide great opportunities for recreation in these areas.”

About the Enviva Forest Conservation Fund
The Enviva Forest Conservation Fund is a $5 million, 10-year program established by Enviva in December 2015 to protect environmentally sensitive bottomland and wetland forests. Administered by the U.S. Endowment for Forestry and Communities, the Fund awards grants annually to nonprofit organizations and government agencies for conservation projects. Learn more at http://envivaforestfund.org.

About the U.S. Endowment for Forestry and Communities
The U.S. Endowment for Forestry and Communities is a not-for-profit public charity working collaboratively with partners in the public and private sectors to advance systemic, transformative, and sustainable change for the health and vitality of the nation’s working forests and forest-reliant communities. To learn more about the Endowment, please visit our website at www.usendowment.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220920006011/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye